ACTHIV: LOOKING FORWARD. John G. Bartlett Johns Hopkins University School of Medicine
|
|
- Alexandra Hutchinson
- 6 years ago
- Views:
Transcription
1 ACTHIV: LOOKING FORWARD John G. Bartlett Johns Hopkins University School of Medicine
2 Learning Objectives Identify major issues in HIV care and care delivery for that will impact your practice, including: Cost, testing and retention in care Treatment of HCV co-infection, New testing methods for HIV care Genetic testing to facilitate drug selection Treatment of immune activation
3 Disclosure I will be discussing investigational uses of future agents, which I will disclose during the presentation.
4 GUIDELINES: DHHS (2011) IAS-USA (2010) When to start Virtually all with HIV who are ready and not nonprogressors What to start TDF/FTC + ATV/r, EFV, DRV/r or RAL When to change VL >200 What to change to Multiple options Presentation at 2011 CROI When to Start: 0 What to Start: 1
5 TOPICS INCLUDED Generic Drugs: Cost, RWCA, Obama Care Prevention: ART and TNT Hepatitis C co-infection Personalized HIV care Testing: Point-of-Care (POC) Strategies: Intensification, Nuc-sparing Operational challenges
6 GENERIC DRUGS
7 PATENT LIFE: YEAR OF NDA TC SQV X X NVP X EFV ABC X X
8 WHO/UNAIDS, 2002
9 CIPLA -- $72/yr AWP -- $370/yr
10 WHY IS DRUG COST AN ISSUE? Expect number treated to increase a lot Increased survival add 35,000-40,000/year Increased testing (21% undetected) Guidelines treat nearly everyone Ryan White Care Act Waiting line > 6,200 Flat funded
11 PREVENTION
12 PREVENTION Pre-exposure prophylaxis Test and Link to Care (TLC) Community viral load
13 iprex: Updated Report on Effectiveness of PrEP 2,499 MSM randomized 1:1 to received TDF/FTC or placebo F/U was continued for 8 weeks after stopping study drug P=0.002 N= Placebo FTC/TDF Grant R, et al. 18th CROI; Boston, MA; February 27-March 2, Abst. 92.
14 RISK OF SEXUAL TRANSMISSION: PARTNERS IN PREVENTION (2011 CROI: Abstr. 135) /act Female Male Male Female Risk RR Log increase VL 2.8 Genital ulcer 2.6 Condom use 0.2 Male circumcision 0.5 Emtricitabine and tenofovir 0.6 disoproxil fumarate use (Vaginal microbicide) 0.7
15 RISK OF SEXUAL TRANSMISSION: PARTNERS IN PREVENTION (2011 CROI: Abstr. 135) /act Female Male Male Female Risk RR Log increase VL 2.8 Genital ulcer 2.6 Condom use 0.2 Male circumcision 0.5 Emtricitabine and tenofovir 0.6 disoproxil fumarate use (Vaginal microbicide) 0.7
16 PROPHYLAXIS OF HIV: PREVENTION IN MSM (MMWR 2011;60:65) Interim Guidance: Use only in very high risk MSM R/O HIV Assure use of condoms, etc. Must monitor users q 3-4 months for HIV, adherence and toxicity Not FDA-approved Concerns safety and resistance BUT:... Potential for HIV prevention in high risk patient.
17 Transmission rate per 100 person-years Plasma HIV RNA Predicts Likelihood of HIV Transmission All subjects Male-to-Female Transmission Female-to-Male Transmission Quinn et al. N Engl J Med Viral load (HIV-1 RNA copies/ml) and HIV transmission
18 UNIVERSAL TESTING WITH IMMEDIATE ART AS A STRATEGY TO ELIMINATE HIV TRANSMISSION (Granich R, et al WHO, Lancet 2009;373:48) Method: Mathematical models used to calculate reproduction number and dynamics of the HIV epidemic
19 Granich R, et al WHO, Lancet 2009;373:48
20 Granich R, et al. Lancet 2009;373:48 Conclusion: Models suggest universal testing and immediate ART for all HIV infected persons could relatively, rapidly eliminate HIV transmission and bring HIV/AIDS under control.
21 WHY TLC WON T WORK (Burns DN. Clin Infect Dis 2010;51:725) Calculations to justify conclusions: wrong Based on heterosexual sex Failed to account for disinhibition Resistance rates at 3%/yr Acute infection accounts for 9% Application problems in the US are huge Annual testing, but 50% never tested Link to care: Current 60% Achieve NDV in treated
22 SAN FRANCISCO (PLoS One 2010;6:e11068)
23 Viral Load Thresholds on July 1 of each Calendar Year from in the Johns Hopkins HIV (Moore) Clinic Internal Johns Hopkins Data
24 HEPITITIS C CO-INFECTION
25 Excitement grows for potential revolution in hepatitis C virus treatment Data from a late-stage trial of the most advanced of a new class of drugs targeting the hepatitis C virus protease fuel hopes for major improvements in treatment outcomes.
26 Selected drugs in phase II or II trials for the treatment of HCV*
27 HEPATITIS C No. Co-infected (US): 300,000 New drugs: PIs Bocepravir and Telaprevir Cure rates (with PegINF/rib): 70% Treatment: 12 wks tid ADRs: Anemia, rash (Telaprevir) Viral response: VL <500 at 4 weeks Resistance: 1-5% (minor variants) BUT: PegINF/rib guard Best response: 1b and IL28B SNP C/C
28 Telaprevir Drug Interactions with ARVs TVR dose ARV TVR AUC TVR Cmin ARV AUC ARVCmin TVR 750 mg TID TVR 1250 mg TID TVR 1500 mg BID ATV/r 0.80 ( ) DRV/r 0.65 ( ) FPV/r 0.68 ( ) LPV/r 0.46 ( ) 0.85 ( ) 0.68 ( ) 0.70 ( ) 0.48 ( ) 1.17 ( ) 0.60 ( ) 0.53 ( ) 1.06 ( ) EFV 0.82 TDF 0.82 ( ) 0.75 ( ) ( ) 1.10 ( ) EFV 0.85 TDF 0.80 ( ) 0.52 ( ) ( ) 1.10 ( ) Van Heeswijk R, et al. 18th CROI; Boston, MA; February 27-March 2, Abst ( ) 0.58 ( ) 0.44 ( ) 1.14 ( ) 0.90 ( ) 1.17 ( ) 0.89 ( ) 1.06 ( )
29 Telaprevir Drug Interactions with ARVs TVR dose ARV TVR AUC TVR Cmin ARV AUC ARVCmin TVR 750 mg TID TVR 1250 mg TID TVR 1500 mg BID ATV/r 0.80 ( ) DRV/r 0.65 ( ) FPV/r 0.68 ( ) LPV/r 0.46 ( ) EFV 0.85 ( ) 0.68 ( ) 0.70 ( ) 0.48 ( ) 1.17 ( ) 0.60 ( ) 0.53 ( ) 1.06 ( ) TDF 0.82 ( ) 0.75 ( ) 0.82 ( ) 1.10 ( ) EFV 0.85 TDF 0.80 ( ) 0.52 ( ) ( ) 1.10 ( ) Van Heeswijk R, et al. 18th CROI; Boston, MA; February 27-March 2, Abst ( ) 0.58 ( ) 0.44 ( ) 1.14 ( ) 0.90 ( ) 1.17 ( ) 0.89 ( ) 1.06 ( )
30 PROTON STUDY: PSI PR (Nelson EASL 4/1/11)
31 WHAT CLINICIANS NEED TO KNOW ABOUT HCV 1. The new drugs will be a game changer 2. Expect 2 PIs in May/June 2011; other classes in % of people with HCV do not know it 4. Screening test HCV serology HCV VL 5. May need to prioritize on basis of severity. If can wait should wait 6. It will be expensive $40-50K
32 HCV/HIV: WHAT WILL HAPPEN PIs: Approval expected 2011 (? HIV/HCV) Allowable Third drugs ATV/r, EFV, RAL Cost PIs: $30K, Peg INF/rib -- $40K Candidates: 1) Urgency based on biopsy fibrosis stage >3, 2) Probability of cure 1b and IL28B SNP C/C Can they wait? New drug (nucleotides, etc); access 2013 and market
33 GENETIC PREDICTORS
34 PHARMACOGENETIC MARKERS AND PREMATURE DISCONTINUATIONS OF RECOMMENDED ART AGENTS (Swiss Cohort Study. JID 2011:203:246) Issue: Utility of pharmacogenetic markers for drug selection Method: Genotyping of 23 genetic markers genetic score correlated with discontinuation rates for TDF, EFV, LPV, ATV and (ABC).
35 PREDICT: HLA-B*5701 GENETIC TESTING PRIOR TO ABC (Mallal S. NEJM 2008;358:568) Method: 1650 pts, 314 centers Australia and Europe Results: Test No test Suspected HSR 3.4% 7.8% Confirmed HSR 0 2.7% Conclusion: Neg. predictive value: 100% Pos. predictive value: 48% Update: NPV=100% to date (S. Mallal. 3/10/11)
36 Mallal S. NEJM 2008;358:568
37 Mallal S. NEJM 2008;358:568
38 TESTING: POC TESTS
39 HIV-1/2 Ag/Ab Combo Reading the Result Control Patient Positive For Antibodies Positive For p24 Antigen Positive For Antibodies AND p24 Antigen Negative
40 CD4 test Consisting of the CD4 Analyzer and the CD4 cartridge the CD4 test is a unique and breakthrough technology able to provide an absolute CD4 count from whole blood. Alere CD4 Analyzer Alere CD4 Test Cartridge
41 LAB TECHNICIANS NURSES
42 POC TESTING HIV
43 POC TESTING HIV CD4 test 2011
44 POC TESTING HIV CD4 test 2011 HIV Viral load 2012
45 POC TESTING HIV CD4 test 2011 HIV Viral load 2012 Home test (?)
46 ORAL SAMPLE HIV TESTING
47 NEW ART and ART STRATEGIES
48
49 RILPIVIRINE (B-TRIPLA) Trials vs. EFV: ECHO and THRIVE VL at 48 weeks <50 c/ml: 83% and 84% Tolerance (D/C rate) RPV: 8% vs. 3% Virologic (TLOVR) EFV: 9% vs. 5% Resistance: RAM ETR NRTI RPV 138K R 184V (68%) EFV 103N S 184V (32%)
50 TREATMENT PRINCIPLES Requirement: > 2 active drugs from 2 classes Monotherapy: 3 PI/r regimens, 9 trials NONE (DRV/r) Intensification: Goal to CD4 count, immune activation or get that last virion NONE NRTI-sparing: 12 regimens, 24 trials NONE (DRV/r, TRIO, LVP/r/EFV) Level of Evidence: RCTs
51 STRUCTURAL ISSUES
52 The Treatment Cascade From HIV Diagnosis Through Suppressed Viral Load. Greenberg A E et al. Health Aff 2009;28: by Project HOPE - The People-to-People Health Foundation, Inc.
53 The spectrum of engagement in HIV care in the United States spanning from HIV acquisition to full engagement in care, receipt of antiretroviral therapy, and achievement of complete viral suppression. Gardner E M et al. Clin Infect Dis. 2011;52: The Author Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please journals.permissions@oup.com.
54 OPERATIONAL ISSUES Test: 51% US adults never tested Screening: 30% fail to get confirmatory test Entry/retention in care: 30% never enter care: Source: CDC
55 OPERATIONAL ISSUES Test: 51% US adults never tested Make it a Medicare PI Screening: 30% fail to get confirmatory test Entry/retention in care: 30% never enter care:
56 OPERATIONAL ISSUES Test: 51% US adults never tested Make it a Medicare PI Screening: 30% fail to get confirmatory test Two rapid tests (like Africa) or entry to care with positive screening test Entry/retention in care: 30% never enter care:
57 OPERATIONAL ISSUES Test: 51% US adults never tested Make it a Medicare PI Screening: 30% fail to get confirmatory test Two rapid tests (like Africa) or entry to care with positive screening test Entry/retention in care: 30% never enter care: P4P4P
58 C-REACTIVE PROTEIN
59 SHOULD WE DO SOMETHING ABOUT IMMUNE ACTIVATION? CONTEMPORARY AIDS ISSUE: Immune activation (AIDIAS) TESTING: Utility of inflammatory coagulation markers (hscrp, IL-6, D-dimeR TREATMENT: Statins?
60 BIOMARKERS OF IMMUNE ACTIVATION: SMART VS. MESA (Neuhaus J, et al. JID 2010;201:1788)* Marker SMART MESA % n=494 n=5386 hs CRP ** 38% IL ** 60% D-dimer ** 49% *Data limited to persons years **P <0.001
61 45 mil CRP tests in 295,631 people. Mortality for 22,962 with subacute elevations (1-10 mg/l) (Currie CJ. Heart 2008;94:459)
62 CATEGORY CHANGE: IMPACT ON MORTALITY Currie CJ. Heart 2008;94:459
63 JUPITER TRIAL: R. Kones* Impact of Rosuvastatin on hscrp and mortality LDL Chol hscrp Event rate HR >70 > >70 < <70 > <70 < *Drug Design, Dev Ther 2010;4:383
64 IMMUNE ACTIVATION* hscrp: Readily available and most used marker by cardiologists, BUT controversial Statins: Use for pleitropic (non-lipid effect) is controversial Perspective: CVD Risks 1) address all issues smoking, diabetes, BP, diet, exercise and 2) Keep LDL <70 *Wendy Post, MD (Preventive Cardiology)
65 MANAGEMENT ISSUES When to start, what to start: No longer argued or defended Cost of care: Will be issue May lose RWCA Prevention: Test and Treat (priority, not PrEP) HCV/HIV: Need providers Genetic predictors: Personalized medicine POC: Ab Ab/Ag CD4 VL New drugs: One pill (09-1, 011-2, 012-3, 013-4) Structural: Simple solutions Learn from Africa, syphilis and P4P4P Immune activation: Measure (?) and treat (?)
ART for HIV Prevention:
ART for HIV Prevention: KENNETH H. MAYER, M.D. Brown University/The Fenway Institute August 22, 2009 APPROACHES TO PREVENT HIV TRANSMISSION DECREASE SOURCE OF INFECTION Barrier Protection Treat STI Antiretroviral
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationTreatment of chronic hepatitis C in HIV co-infected patients
Treatment of chronic hepatitis C in HIV co-infected patients Vicente Soriano Department of Infectious Diseases Hospital Carlos III, Madrid, Spain The most prevalent chronic viral infections in humans HBV
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More informationCases from the Clinic(ians): Case-Based Panel Discussion
Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,
More informationSwitching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationEvolving HIV Treatment Paradigms What we need to know
Evolving HIV Treatment Paradigms What we need to know Benjamin Young International Association of Providers of AIDS Care Washington, DC, USA Evolving HIV Treatment Paradigms When/who to treat Better medicines
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationHIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP
HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationWhat are the most promising opportunities for dose optimisation?
What are the most promising opportunities for dose optimisation? Andrew Hill Liverpool University, UK Global Financial Crisis How can we afford to treat 15-30 million people with HIV in the future? Lowering
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationPrEP: Pre Exposure Prophylaxis
PrEP: Pre Exposure Prophylaxis Lyn Stevens, NP, MS, ACRN Deputy Director Office of the Medical Director NYS Department of Health, AIDS Institute Faculty Disclosure Lyn Stevens No relationships to disclose
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationPotential Issues in Treating HIV/HCV co-infection with new HCV antivirals
State of the Art in Hepatitis C Virus Infection in HIV/HCV-Coinfected Patients FORMATTED: 11/17/15 David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California
More informationThe Future of HIV: Advances in Drugs and Research. Shauna Gunaratne December 17, 2018
The Future of HIV: Advances in Drugs and Research Shauna Gunaratne December 17, 2018 Overview Epidemiology Science of HIV How HIV treatment and management have changed over the years New medicines and
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationThe Eras of the HIV Epidemic
The Eras of the HIV Epidemic 1930-1980 1981-1986 1987-1995 1996-2005 2nd Gen. HAART 2006-2011 2006: Disproportionate distribution of HIV 2006: Gates and Clinton at International AIDS conference announce
More informationObjectives. HIV in the Trenches HIV Update for the Primary Care Provider, An Overview The HIV Continuum of Care.
1:30 2:30pm HIV Update SPEAKER Gordon Dickinson, MD Presenter Disclosure Information The following relationships exist related to this presentation: Gordon Dickinson, MD, has no financial relationships
More informationHIV Treatment Evolution. Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare
HIV Treatment Evolution Kimberly Y. Smith MD MPH Vice President and Head, Global Research and Medical Strategy Viiv Healthcare Overview of the Evolution of Antiretroviral Therapy Early Treatment 1987
More informationImmunologic Failure and Chronic Inflammation. Steven G. Deeks Professor of Medicine University of California, San Francisco
Immunologic Failure and Chronic Inflammation Steven G. Deeks Professor of Medicine University of California, San Francisco Plasma HIV RNA (log) 6 5 4 3 2 52 year old HIV+/HCV+ man presents with symptomatic
More informationRoy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City
PrEP 2013 Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Slide #2 U.S.: New HIV Infections Per Year ~50,000
More informationCombination HIV Prevention Research Carl W. Dieffenbach, Ph.D.
Combination HIV Prevention Research Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID, NIH October 13, 2011 Multiple strategies needed to assemble a wellrounded prevention toolkit Know the epidemics
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationFirst-Line Antiretroviral Therapy for Treatment and Prevention:
First-Line Antiretroviral Therapy for Treatment and Prevention: The Past, Present and Future Best Options Joel Gallant, MD, MPH Johns Hopkins University School of Medicine IAS-USA Guidelines 7/2008: When
More informationSusan L. Koletar, MD
HIV/AIDS Susan L. Koletar, MD Division Director, Infectious Diseases Professor of Internal Medicine Department of Internal Medicine The Ohio State University Wexner Medical Center HIV through the Decades
More informationPrEP for Women: HIV Prevention in Family Planning Settings
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention PrEP for Women: HIV Prevention in Family Planning Settings Dawn K. Smith, MD, MS, MPH Division of HIV/AIDS Prevention dsmith1@cdc.gov
More informationI. HIV Epidemiology. HIV Infection A Primer. Objectives. Disclosures 7/18/2014
Objectives HIV Infection A Primer Discuss the worldwide and domestic epidemiology of HIV infection Review HIV Biology Review HIV Transmission and Prevention Review HIV diagnosis Describe the approaches
More informationHIV Treatment: State of the Art 2013
HIV Treatment: State of the Art 2013 Daniel R. Kuritzkes, MD Chief, Division of Infectious Diseases Brigham and Women s Hospital Professor of Medicine Harvard Medical School Success of current ART Substantial
More informationTreatment strategies for the developing world
David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia First line standard of care First line in the developing world First line failure
More informationGetting Prepped for PrEP. Ken Ho, MD, MPH World AIDS Day
Getting Prepped for PrEP Ken Ho, MD, MPH World AIDS Day Objectives HIV epidemiology What is PrEP? Does it Work? Who gets PrEP? How do I prescribe PrEP What to do at the first visit? What to do at follow
More informationNumber of Contributing Patients
Course Director John Bartlett, MD Professor, Johns Hopkins University School of Medicine Baltimore, Maryland Faculty José Arribas, MD Senior Attending Physician, HIV Unit Hospital de La Paz Madrid, Spain
More informationBHIVA antiretroviral treatment guidelines 2015
BHIVA antiretroviral treatment guidelines 2015 Duncan Churchill Brighton & Sussex University Hospitals NHS Trust Laura Waters Mortimer Market Centre, CNWL Duncan Churchill GENERAL POINTS & WHEN TO START
More informationART FOR HIV PREVENTION: PANACEA OR PANDORA S BOX? KENNETH H. MAYER, M.D.
ART FOR HIV PREVENTION: PANACEA OR PANDORA S BOX? KENNETH H. MAYER, M.D. HIV TRANSMISSION SIGNIFICANT, LOW PROBABILITY EVENT (
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationAdvances in HIV science and treatment. Report on the global AIDS epidemic,
HIV biomolecular advances and treatment updates David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia UNAIDS: global l HIV infections
More informationUsing anti-hiv drugs for prevention
Using anti-hiv drugs for prevention Highlights from AIDS 2012 (and 2 nd International Workshops on Treatment as Prevention) Tim Rogers, trogers@catie.ca Using anti-hiv Drugs for Prevention Outline Treatment
More informationHIV Update. On The Cutting Edge A Chronic Disease. Rhett M Shirley, MD
HIV Update On The Cutting Edge A Chronic Disease Rhett M Shirley, MD CDC Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic characteristics,
More informationProvisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons
INVITED ARTICLE HIV/AIDS Kenneth H. Mayer, Section Editor Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons David L. Thomas,
More informationWhat's new in the WHO ART guidelines How did markets react?
WHO 2013 ARV Guidelines What's new in the WHO ART guidelines How did markets react? Dr. J. Perriëns Coordinator, HIV Technology and Commodities HIV department, WHO, Geneva When to start in adults Starting
More informationMedical Challenges of HIV/AIDS pandemic: The WHO perspective. SOLTHIS HIV Forum
Medical Challenges of HIV/AIDS pandemic: The WHO perspective SOLTHIS HIV Forum Marco Vitoria HIV/AIDS Department World Health Organization September 2013 Topic 2002 2003 2006 2010 2013 When to start 1
More informationDisclosure. Learning Objectives. Epidemiology. Transmission. Risk of Transmission PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION 50,000.
Disclosure PRE-EXPOSURE PROPHYLAXIS (PREP) FOR HIV PREVENTION I have no financial interest in and/or affiliation with any external organizations in relation to this CE program. DaleMarie Vaughan, PharmD
More information2016 Perinatal Treatment Guidelines Update
Mountain West AIDS Education and Training Center 2016 Perinatal Treatment Guidelines Update Shireesha Dhanireddy, MD Associate Professor of Medicine, University of Washington 2 November 2016 This presentation
More informationSA HIV Clinicians Society Adult ART guidelines
SA HIV Clinicians Society Adult ART guidelines In draft format Graeme Meintjes (on behalf of the guidelines committee) Selected topics When to start ART First-line Second-line Third-line Patients with
More informationBHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy. START & other changes
BHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy START & other changes Contents Introduction & treatment aims Major changes When to start What to start BHIVA: what
More informationHIV and contraception the latest recommendations
1 8-11 June 2015, Chiang-Mai HIV and contraception the latest recommendations Mary Lyn Gaffield, Sharon Phillips, Rachel Baggaley, Petrus Steyn, and Marleen Temmerman 2 Medical eligibility criteria for
More informationAdvancing Treatment 2.0: Progress on the 2013 Consolidated Guidelines What s new
Advancing Treatment 2.0: Progress on the 2013 Consolidated Guidelines What s new H I V / A I D S D e p a r t m e n t WHO HQ Meg Doherty, MD, MPH, PhD Coordinator Treatment and Care November 5, 2012 1 Overview
More informationThe results of the ARTEN study. Vicente Soriano Hospital Carlos III, Madrid, Spain
The results of the ARTEN study Vicente Soriano Hospital Carlos III, Madrid, Spain Nevirapine: a well-defined efficacy and tolerability profile High efficacy levels 1 3 Well-defined safety profile 4 Favourable
More informationClinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline
Clinical Pharmacology of DAA s for HCV: What s New & What s In Pipeline Kirk Bertelsen, PhD Clinical Pharmacology Janssen Pharmaceuticals, Research & Development 4/24/2013 1 Incivo Simeprevir 2 Janssen
More informationDoes Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Does Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosure The speaker serves as a consultant to, and has received
More informationThe Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN
The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure
More informationEpidemiology. Update From the 2019 Conference on Retroviruses and Opportunistic Infections. Learning Objectives
Slide 1 of 51 Update From the 2019 Conference on Retroviruses and Opportunistic Infections Jeffrey L. Lennox, MD Professor of Medicine Associate Dean for Clinical Research Emory University Atlanta, Georgia
More informationJoseph Cofrancesco Jr, MD, MPH, FACP
Friday Case Series Joseph Cofrancesco Jr, MD, MPH, FACP Associate Professor of Medicine Director and Johns Hopkins Institute for Excellence in Education Professor of Medicine Join us on Facebook Follow
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationHIV-Associated Inflammation: Do the drugs matter? Jun 15, 2018 Darrell H. S. Tan MD FRCPC PhD
HIV-Associated Inflammation: Do the drugs matter? Jun 15, 2018 Darrell H. S. Tan MD FRCPC PhD Faculty/Presenter Disclosure Faculty: Darrell H. S. Tan Relationships with financial sponsors / potential for
More informationEACS 2011 October 12-15, 2011 Belgrade, Serbia IDSA October 20-23, 2011 Boston, Massachusetts Course Director. Faculty
EACS 2011 October 12-15, 2011 Belgrade, Serbia IDSA October 20-23, 2011 Boston, Massachusetts Course Director John Bartlett, MD Professor, Johns Hopkins University School of Medicine Baltimore, Maryland
More informationTunisian recommendations on ART : process and results
Second Arab Congress of Clinical Microbiology and Infectious Diseases May 24-26, 2012. Tunisian recommendations on ART : process and results M. BEN MAMOU UNAIDS Email: BenmamouM@unaids.org M. CHAKROUN
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationProfessor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA
17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Professor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA 6-8 April 2011, Bournemouth International Centre 17 TH ANNUAL
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationSecond and third line paediatric ART strategies
Second and third line paediatric ART strategies Dr. Marape Marape Assistant Professor Ohio University School of Health Professions Gaborone, Botswana Marape Marape MB, BCh, BAO, MPH, PhD Assistant Professor
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationOn the Horizon for Consideration: Biomedical Advances in HIV Prevention
On the Horizon for Consideration: Biomedical Advances in HIV Prevention Francisco Ruiz, MS Senior Manager, National Alliance of State and Territorial AIDS Directors New Jersey Governor's Advisory Council
More informationHIV/hepatitis co-infection. Christoph Boesecke Department of Medicine I University Hospital Bonn Germany
HIV/hepatitis co-infection Christoph Boesecke Department of Medicine I University Hospital Bonn Germany Clinical Management and Treatment of HBV and HCV Co-infection in HIVpositive Persons Hepatitis B
More information12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter
EACS 2009 11-14, November 2009 Cologne, Germany Course Director Jürgen K. Rockstroh, MD Co-Chairman, 12th European AIDS Conference Professor, University of Bonn Bonn, Germany Faculty Calvin Cohen, MD,
More informationSouth African Guidelines for the Safe Use of. Dr. Oscar Radebe
South African Guidelines for the Safe Use of PrEP in MSM Dr. Oscar Radebe Background Globally MSM(men who have sex with men) have been disproportionately at high risk of HIV transmission. Biological &
More informationWhere are we going after effectiveness studies?
Where are we going after effectiveness studies? Nyaradzo M. Mgodi (MBChB, MMed) UZ-UCSF Collaborative Research Program Harare, Zimbabwe MTN Annual Meeting 28 March 2011, Arlington, VA Introduction 30 years
More informationFertility Desires/Management of Serodiscordant HIV + Couples
Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University
More informationSimplifying HIV Treatment Now and in the Future
Simplifying HIV Treatment Now and in the Future David M. Hachey, Pharm.D., AAHIVP Professor Idaho State University Department of Family Medicine Nothing Disclosure 1 Objectives List current first line
More informationHIV Reproductive Health: Conception Options in the Era of PrEP
HIV Reproductive Health: Conception Options in the Era of PrEP Meg Sullivan, MD Director, HIV Clinical Programs, Section of Infectious Diseases Boston Medical Center Boston University School of Medicine
More informationHIV Prevention. David Cooper, MD, DSc Director and Professor, Kirby Institute University of New South Wales Sydney, Australia
HIV Prevention David Cooper, MD, DSc Director and Professor, Kirby Institute University of New South Wales Sydney, Australia HIV Care/Prevention Continuum Test Engage, Counsel, Monitor and Support Retain,
More informationHow to best manage HIV patient?
How to best manage HIV patient? 1 2 Treatment Treatment Failure success HIV therapy = a long life therapy Why do we want to change a suppressive ART? Side effect Comorbidities Reduce drug burden How to
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationHIV-HCV coinfection. Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland
HIV-HCV coinfection Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures Principal investigator for research grants Funds paid to Johns Hopkins
More informationBiomedical Prevention Update Thomas C. Quinn, M.D.
Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global
More informationWHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES?
WHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES? Today s Webinar will be starting soon For the audio portion of this meeting: Dial 1-855-702-5382 Enter participant code 596-825-4701# Guidelines for online
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationHIV Prevention Strategies HIV Pre-exposure prophylaxis
HIV Prevention Strategies HIV Pre-exposure prophylaxis Michael Martin, MD, MPH Director HIV Research Program Thailand MOPH U.S. CDC Collaboration The findings and conclusions in this presentation are those
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationHepatitis C in HIV Coinfection. Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF
Hepatitis C in HIV Coinfection Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Disclosures I have received research grant support to UCSF related to HCV from the following: Abbvie
More informationHIV - Preventing New Infections: New Options, Readjusted Approaches
HIV - Preventing New Infections: New Options, Readjusted Approaches Ronald P. Hattis, MD, MPH Beyond AIDS Foundation Presented at Loma Linda University December 6, 2013 1 Thesis (Summary) As of 2013-14,
More informationPre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention
Pre exposure Prophylaxis (PrEP): Stepping Up HIV Prevention Dawn K. Smith, MD, MS, MPH Centers for Disease Control and Prevention The findings and conclusions in this presentation have not been formally
More informationClinical cases: HIV/HCV coinfection
Clinical cases: HIV/HCV coinfection José Vicente Fernández-Montero Hospital Carlos III, Madrid Case #1 General considerations about antiviral therapy CASE # 1 43 year-old, male patient Former IDU No prior
More informationWhen to start: guidelines comparison
The editorial staff When to start: guidelines comparison The optimal time to begin antiretroviral therapy remains a critical question for the HIV field, and consensus about the appropriate CD4+ cell count
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationPrEP for HIV Prevention. Adult Clinical Guideline from the New York State Department of Health AIDS Institute
PrEP for HIV Prevention Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org Purpose of the PrEP Guideline Raise awareness of PrEP among healthcare
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More informationSwitching strategies and ARV treatment costs
February 2014 Switching strategies and ARV treatment costs Josep M Llibre/Bonaventura Clotet Fundació Lluita contra la SIDA Hosp Univ Germans Trias i Pujol Badalona Rationale. Spain is under a huge economic
More informationOR: Steps you can take in the clinic to prevent HIV infections
Implementing Changes to Reduce HIV Incidence: Synergies between Public Health and Primary Care Kevin Ard, MD, MPH Brigham and Women s Hospital, Massachusetts General Hospital, and the Fenway Institute
More informationOverview of 2013 WHO consolidated ARV guidelines and update plans. Marco Vitoria HIV/AIDS Department WHO Geneva September 2014
AMDS ANNUAL STAKEHOLDERS AND PARTNERS MEETING Overview of 2013 WHO consolidated ARV guidelines and update plans Marco Vitoria HIV/AIDS Department WHO Geneva September 2014 AMDS ANNUAL STAKEHOLDERS AND
More informationDidactic Series. CROI New Antiretroviral Therapies. Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016
Didactic Series CROI 2016 - New Antiretroviral Therapies Daniel Lee, MD Clinical Professor of Medicine UCSD Medical Center Owen Clinic July 14, 2016 This project is supported by the Health Resources and
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationARV Consolidated Guidelines 2015
ARV Consolidated Guidelines 2015 This document outlines the draft list of PICO questions to support systematic review process for the 2015 ARV guidelines process. PICO questions are grouped by clinical
More information